Global Castleman Disease Treatment Market - 2022-2029

Global Castleman Disease Treatment Market - 2022-2029

Market Overview

The Global Castleman Disease Treatment Market is expected to grow at a high CAGR during the forecasting period (2022-2029).

Castleman disease is a rare disorder in which cells in the lymph nodes grow out of control. The most prevalent form of the disorder (unicentric Castleman disease) involves a single lymph node in the chest or belly. Depending on the patient's type of Castleman disease, treatment and prognosis will differ. Surgery is frequently successful in treating the type that involves only one lymph node.

Market Dynamics

Clinical trials conducted by the research institutes for the treatment of Castleman Disease are expected to drive market growth.

The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Moreover, The Peking Union Medical College Hospital in Beijing, China, sought participants for a clinical trial examining the efficacy and safety of the drugs bortezomib, cyclophosphamide, and dexamethasone (BCD regimen). Thus, the market is expected to drive in the forecast period from the above statements.

Restraint:

Due to the disease's low prevalence rate and a lack of knowledge about it, there is a lack of awareness. The Patent expiry of several companies associated with the high cost of treatment are factors the market is expected to hamper in the forecast period.

COVID-19 Impact Analysis

The COVID-19 pandemic has moderately impacted healthcare systems and the market. Anti-IL6 drugs like siltuximab and tocilizumab are also being used to treat COVID-19-induced cytokine storms in some critically ill patients. Moreover, Anti-IL6 medicines like siltuximab and tocilizumab are now well-established as viable treatments for some individuals with idiopathic multicentric Castleman disease. These drugs alleviate symptoms in the short term, but they are also safe and provide long-term disease control in responders. During the COVID-19 pandemic, the CDCN understands a supply shortfall of siltuximab and tocilizumab. The CDCN is concerned about the availability of these important medications for Castleman Disease patients. The CDCN learned that the producers of siltuximab and tocilizumab are committed to providing the drugs to individuals with Castleman Disease. Therefore, many companies will vary to other geographic regions to ensure that products remain available and protect their supply chain. Thus, from the above statements, the market got affected, and it is expected to gain traction quickly with the resumption of the economic activities.

Segment Analysis

Immunotherapy segment is expected to hold the largest market share in castleman disease treatment market

The immunotherapy segment is expected to dominate in 2021. The segment is benefitted because drugs like siltuximab (Sylvant) and rituximab (Rituxan) can inhibit the function of a protein that is overproduced in persons with multicentric Castleman disease. Moreover, medicines and other therapies to control cell overgrowth are commonly used to treat multicentric Castleman disease. Treatment options vary depending on the severity of your illness and whether the patient has HIV, HHV-8, or both. Therefore, these agents do not only control symptoms short-term but continued administration to responders is safe and provides durable disease control. Thus, the market segment is expected to hold the largest market share in the forecast period from the above statements.

Geographical Analysis

North America region holds the largest market share in the global castleman disease treatment market

In 2021, North America accounted for the highest revenue share. The increasing prevalence of idiopathic multicentric Castleman disease (iMCD), well-established infrastructure, companies focusing on research & development and performing clinical trials and the presence of major players as well as government measures that aid medicine development for orphan diseases are some of the factors the market is expected to boost in the forecast period. For instance, it is estimated that 6500 to 7700 new cases are diagnosed each year in the United States; approximately 1000 of those are HHV-8–associated multicentric Castleman disease (HHV-8–associated MCD), and 1000 are HHV-8–negative MCD. Moreover, The Castleman Disease Collaborative Network (CDCN) has teamed up with the University of Pennsylvania and the University of Arkansas for Medical Sciences to conduct a study of sirolimus, an investigational medicine, for adults with idiopathic multicentric Castleman disease (iMCD) who have failed to respond to anti-IL-6 therapies. Siltuximab (Sylvant) and tocilizumab are two anti-IL-6 drugs (Actemra). Thus, the North American region is expected to hold the largest market share in the forecast period from the above statements.

Competitive Landscape

Major key players in the castleman disease treatment market are EUSA Pharma, Johnson & Johnson Services, Inc., Genentech USA, Inc., F. Hoffmann-La Roche Ltd, Amgen Inc., Bristol-Myers Squibb Company, Par Pharmaceutical, Exela Pharma Sciences.

EUSA Pharma:

Overview:

EUSA Pharma was founded in March 2006. It is a newly-established, profitable specialty pharmaceutical company with global reach from its UK headquarters and commercial operations across Europe and the USA. It is focused on oncology and rare disease, continuously striving to confront gaps in patient care. EUSA Pharma also has a wide distribution network of commercial partners in Europe, the Middle East, Asia and Latin America. It makes products available in approximately 40 countries worldwide through this broad international platform.

­Product Portfolio:

SYLVANT (siltuximab): It is the first and only FDA/EMA approved therapy for idiopathic Multicentric Castleman Disease (iMCD) and is recommended as the preferred first line therapy by clinical guidelines.

Why Purchase the Report?

Visualize the composition of the castleman disease treatment market segmentation by type, diagnosis, treatment, end user, distribution channel, and region highlighting the key commercial assets and players.

Identify commercial opportunities in castleman disease treatment market by analyzing trends and co-development deals.

Excel data sheet with thousands of data points of castleman disease treatment market- level 4/5 segmentation.

PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.

Product mapping in excel for the key product of all major market players

The global castleman disease treatment market report would provide an access to an approx. 45+market data table, 40+figures and 180pages.

Target Audience

Service Providers/ Buyers

Industry Investors/Investment Bankers

Education & Research Institutes

Research Professionals

Emerging Companies

Manufacturers